Tirzepatide

Rx only

Part of Weight Loss & Metabolic — Appetite, glucose regulation, and body composition

Clinical dosing reference — FDA-approved only

Shown only for prescription drugs with an FDA label. This describes how these medications are typically prescribed, not a recommendation for you specifically — your prescriber sets and adjusts your actual dose.

Tirzepatide (Zepbound)

Titration: Weekly subcutaneous injection, starting at 2.5 mg (a treatment-initiation dose, not a maintenance dose). After 4 weeks, increased to 5 mg, then optionally in 2.5 mg increments every 4+ weeks up to a maximum of 15 mg.
Maintenance dose: 5 mg, 10 mg, or 15 mg once weekly — many patients stay at 5 mg or 10 mg rather than titrating to the maximum.
Trial results: In the SURMOUNT-1 trial (72 weeks), participants on the 15 mg dose lost a mean of 20.9% of body weight, vs. 3.1% on placebo.

Source: FDA prescribing information (DailyMed) →

Other compounds in this category have no FDA-approved human dosing to cite — see the note below.

Recent research

Live results from PubMed, the NIH’s public database of biomedical literature.

References

Reviewed and approved by an APS editor — not just a raw search result.

Lead-guided prodrug development of small molecules as GLP-1R agonists.

Bioorganic chemistry · 2026 Sep 15 · PMID 42424921

Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.

Obesity pillars · 2026 Sep · PMID 42491427

Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.

Obesity pillars · 2026 Sep · PMID 42518361

Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey.

Obesity pillars · 2026 Sep · PMID 42518363

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.

Endocrinology, diabetes & metabolism · 2026 Sep · PMID 42533465

Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.

Obesity pillars · 2026 Sep · PMID 42440974

Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.

Tissue & cell · 2026 Oct · PMID 42119472

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.

Journal of medical economics · 2026 Dec · PMID 41771166

Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.

Journal of medical economics · 2026 Dec · PMID 42021523

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.

Journal of medical economics · 2026 Dec · PMID 42012820

Get matched with a supplier

Verified suppliers for weight loss & metabolic

No verified suppliers listed for this category yet.

Other peptides in Weight Loss & Metabolic

AOD-9604 Retatrutide Semaglutide

Tirzepatide is an FDA-approved prescription therapeutic available only through a licensed provider. This page does not recommend or endorse use outside of professional medical guidance. See the full disclaimer.